<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Beta blocker properties</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Beta blocker properties</h1>
<div class="graphic"><div class="figure"><div class="ttl">Beta blocker properties</div><div class="cntnt"><table cellspacing="0"><colgroup span="9" width="11%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Alpha blockade</td> <td class="subtitle1">Beta-1 selectivity</td> <td class="subtitle1">ISA</td> <td class="subtitle1">MSA</td> <td class="subtitle1">Lipophilicity</td> <td class="subtitle1">Usual dose*</td> <td class="subtitle1">Half life, hours<sup>¶</sup></td> <td class="subtitle1">Elimination</td> </tr> <tr> <td>Acebutolol</td> <td>No</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Low</td> <td>100 to 400 mg twice per day</td> <td>3 to 4</td> <td> <p>Hepatic (primary)</p> Renal (secondary)</td> </tr> <tr> <td>Atenolol</td> <td>No</td> <td>Yes</td> <td>No</td> <td>No</td> <td>Low</td> <td>50 to 200 mg once daily</td> <td>6 to 9</td> <td>Renal</td> </tr> <tr> <td>Betaxolol</td> <td>No</td> <td>Yes</td> <td>No</td> <td>Yes</td> <td>Low</td> <td>10 to 20 mg once daily</td> <td>14 to 22</td> <td> <p>Hepatic (primary)</p> Renal (secondary)</td> </tr> <tr> <td>Bisoprolol</td> <td>No</td> <td>Yes</td> <td>No</td> <td>No</td> <td>Moderate</td> <td>2.5 to 20 mg once daily</td> <td>9 to 12</td> <td>Renal and hepatic</td> </tr> <tr> <td>Carteolol</td> <td>No</td> <td>No</td> <td>Yes</td> <td>No</td> <td>Low</td> <td>2.5 to 5 mg once daily</td> <td>6</td> <td>Renal</td> </tr> <tr> <td>Carvedilol</td> <td>Yes</td> <td>No</td> <td>No</td> <td>Yes</td> <td>High</td> <td>3.125 to 25 mg twice per day</td> <td>7 to 10</td> <td> <p>Biliary (primary)</p> Hepatic (secondary)</td> </tr> <tr> <td>Esmolol</td> <td>No</td> <td>Yes</td> <td>No</td> <td>No</td> <td>Low</td> <td>IV only 250 to 500 micrograms/kg over one minute then 25 to 50 micrograms/kg per minute as IV infusion; titrate incrementally up to maximum of 300 microgram/kg per minute<sup>Δ</sup></td> <td>9 minutes</td> <td>Blood esterases</td> </tr> <tr> <td>Labetalol</td> <td>Yes</td> <td>No</td> <td>Yes (Beta<sub>2</sub>)</td> <td>Low</td> <td>Moderate</td> <td> <p>IV 20 mg<sup>Δ</sup></p> Orally 100-400 mg two or three times per day</td> <td>3 to 4</td> <td>Hepatic</td> </tr> <tr> <td>Metoprolol tartrate</td> <td>No</td> <td>Yes</td> <td>No</td> <td>Low</td> <td>Moderate</td> <td> <p>IV 1.25 to 5 mg<sup>Δ</sup></p> Orally 25 to 100 mg two times per day</td> <td>3 to 4<br/> (7 to 9 hours in poor metabolizers)</td> <td>Hepatic via CYP2D6 (polymorphic)</td> </tr> <tr> <td>Metoprolol succinate (extended release)</td> <td>No</td> <td>Yes</td> <td>No</td> <td>Low</td> <td>Moderate</td> <td>Orally 50 to 400 mg once daily</td> <td>Apparent half-life prolonged by continuous osmotic release over ~20 hours</td> <td>Hepatic via CYP2D6 (polymorphic)<br/> </td> </tr> <tr> <td>Nadolol</td> <td>No</td> <td>No</td> <td>No</td> <td>No</td> <td>Low</td> <td>40 to 160 mg once daily</td> <td>20 to 24</td> <td>Renal</td> </tr> <tr> <td>Nebivolol</td> <td>No</td> <td>Yes</td> <td>No</td> <td>No</td> <td>High</td> <td>5 to 40 mg once daily</td> <td>10 to 12<br/> (19 to 32 poor metabolizers)</td> <td>Hepatic</td> </tr> <tr> <td>Oxprenolol<sup>◊</sup></td> <td>No</td> <td>No</td> <td>Yes</td> <td>Yes</td> <td>Moderate</td> <td>40 to 80 mg three times per day</td> <td>1.5</td> <td>Hepatic</td> </tr> <tr> <td>Penbutolol</td> <td>No</td> <td>No</td> <td>Yes</td> <td>No</td> <td>High</td> <td>10 to 40 mg once daily</td> <td>5</td> <td>Hepatic</td> </tr> <tr> <td>Pindolol</td> <td>No</td> <td>No</td> <td>Yes</td> <td>Low</td> <td>Moderate</td> <td>5 to 30 mg twice per day</td> <td>3 to 4</td> <td> <p>Hepatic (primary)</p> Renal (secondary)</td> </tr> <tr> <td>Propranolol</td> <td>No</td> <td>No</td> <td>No</td> <td>Yes</td> <td>High</td> <td> <p>IV 1 to 5 mg<sup>Δ</sup></p> Orally 10 to 80 mg two to four times daily</td> <td>3 to 4</td> <td>Hepatic</td> </tr> <tr> <td>Sotalol<sup>§</sup></td> <td>No</td> <td>No</td> <td>No</td> <td>No</td> <td>Low</td> <td>80 to 160 mg twice per day</td> <td>12</td> <td>Renal</td> </tr> <tr> <td>Timolol</td> <td>No</td> <td>No</td> <td>No</td> <td>No</td> <td>Moderate</td> <td>10 to 30 mg twice per day</td> <td>4 to 5</td> <td> <p>Hepatic (primary)</p> Renal (secondary)</td> </tr> </tbody></table></div><div class="graphic_footnotes">ISA: intrinsic sympathomimetic activity; MSA: membrane stabilizing activity; IV: intravenous.<br/>* Range of usual, oral, anti-hypertensive dose, unless "IV" noted.<br/>¶ Duration of hypotensive effect, in general, is longer than may be predicted by serum half-life.<br/>Δ Usual initial IV dose. Subsequent dosing generally needed. See drug monograph for detail.<br/><span class="lozenge">◊</span> Not available in US.<br/>§ Sotalol has independent class III antiarrhythmic activity.</div><div class="graphic_reference">Prepared with data from:

<ol>
<li>Frishman WH, Alwarshetty M. β-Adrenergic blockers in systemic hypertension pharmacokinetic considerations related to current guidelines. Clin Pharmacokinet 2002; 41:505.</li>
<li>Brubacher JR. β-Adrenergic Antagonists. In: Goldfrank's Toxicologic Emergencies, 9th ed, Nelson LS (Ed), McGraw-Hill, New York 2010.</li>
</ol></div><div id="graphicVersion">Graphic 82571 Version 11.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
